Th17 cells/IL-17A shape Pasteurella multocida serotype A infection in murine and rabbit models

Xiongli Liu1, Feiyan Lu1, Tianci Zhang2

  • 1College of Veterinary Medicine, Southwest University, Chongqing, China.

Veterinary Research
|December 16, 2025
PubMed

Insights

Pasteurella multocida serotype A infection impairs T-cell immunity. Activating Th17 cells and IL-17A via the IL-6-JAK2-STAT3 pathway is crucial for host defense against this pathogen.

Area of Science:

  • Immunology
  • Microbiology
  • Pathogen Host Interactions

Background:

  • Pasteurella multocida serotype A (PmA) is a significant zoonotic pathogen causing respiratory disease.
  • Mechanisms of host immune response against PmA remain poorly understood.
  • T-cell mediated immunity is critical for controlling bacterial lung infections.

Purpose of the Study:

  • To elucidate the host immune mechanisms against Pasteurella multocida serotype A infection.
  • To investigate the role of Th17 cells and IL-17A in PmA infection.
  • To identify therapeutic targets for pasteurellosis.

Main Methods:

  • Histopathological analysis and RNA sequencing of infected lungs.
  • In vitro and in vivo manipulation of Th17 cells and IL-17A signaling.
  • Utilizing Stat3 inhibitors and IL-6 knockout mouse models.
  • Assessing protection conferred by recombinant IL-17A in a rabbit infection model.

Main Results:

  • PmA infection led to impaired T-cell activation and a tendency towards Th17/IL-17A pathway stimulation.
  • Host failed to fully activate the Th17 cell/IL-17A axis, crucial for combating PmA.
  • The IL-6-JAK2-STAT3 pathway was identified as essential for Th17 cell/IL-17A activation.
  • Inhibition of this pathway exacerbated disease, while recombinant IL-17A showed protective effects in rabbits.

Conclusions:

  • PmA infection induces a state of T-cell immunodeficiency in mammals.
  • Activation of Th17 cells/IL-17A through the IL-6-JAK2-STAT3 axis is a key defense mechanism against PmA.
  • Targeting Th17 cells/IL-17A presents a promising therapeutic strategy for pasteurellosis and related respiratory bacterial infections.